Effect of probucol on elderly hypercholesterolemic patients in the FAST study

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Hypercholesterolemia is a significant risk factor for cardiovascular disease, particularly in the elderly.
• Lipid-lowering therapies are crucial for managing cardiovascular risk.
• The Fukuoka Atherosclerosis Trial (FAST) provided data on hypercholesterolemic patients, including an elderly subgroup.

Purpose of the Study:

• To conduct a post hoc analysis of the FAST trial.
• To compare the efficacy and safety of lipid-lowering therapy in elderly hypercholesterolemic patients (≥75 years) versus younger patients (<75 years).
• To evaluate the impact of probucol and pravastatin on carotid intima-media thickness (IMT) and cardiovascular events.

Main Methods:

• Post hoc analysis of the Fukuoka Atherosclerosis Trial (FAST) data.
• Included 246 hypercholesterolemic patients, with 76 aged ≥75 years.
• Patients received probucol (500 mg/day), pravastatin (10 mg/day), or diet alone for 2 years.

Main Results:

• Both probucol and pravastatin significantly reduced carotid intima-media thickness (IMT) in patients ≥75 years old.
• Lipid-lowering therapy also significantly reduced IMT in patients <75 years old.
• In patients ≥75 years receiving probucol, there was a trend towards reduced all-cause mortality (RR 0.15) and major coronary events (RR 0.12).

Conclusions:

• Lipid-lowering therapy, including probucol and pravastatin, is effective in reducing IMT in elderly hypercholesterolemic patients.
• Probucol demonstrated potential cardiovascular benefits, reducing the incidence of cardiovascular disease in elderly patients comparable to younger patients.